Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$1.72M$1.72Mno prior Q3 2021 on file Net Income-$4.07M-$4.07Mno prior Q3 2021 on file EPS, diluted—
Operating Income-$4,208,000— The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flow-$1,763,000— Free Cash Flowderived-$1,853,000— Margins · derivedGross margin24.1%
Operating margin-245.1%
Net margin-236.9%
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end